Compare Adaptive Biotechnologies Corp (ADPT) vs Veritone Inc (VERI) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Veritone (VERI) trades at $1.36, up 3.82% on the day, but remains under significant pressure with a bearish technical signal and negative profitability. The company reported a net loss of $111.73 million in 2025, with a net income margin of -123.76%, while revenue declined slightly to $90 million in 2026. Multiple class-action lawsuits filed in July 2026 allege securities fraud related to improper revenue accounting, creating substantial legal overhangs.

The outlook is highly speculative; while the consensus price target of $5.25 implies significant upside, the stock faces severe fundamental challenges and legal risks. Investment opportunity hinges on successful business turnaround and resolution of litigation, but current financial performance and negative cash flow from operations present substantial downside risk.